Forefront Wealth Management Inc. purchased a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 20,891 shares of the biopharmaceutical company's stock, valued at approximately $554,000.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Retirement Wealth Solutions LLC purchased a new stake in shares of Pfizer in the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC bought a new position in Pfizer in the fourth quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer during the fourth quarter worth $28,000. Noble Wealth Management PBC bought a new stake in Pfizer during the 4th quarter valued at $31,000. Finally, Curio Wealth LLC purchased a new position in shares of Pfizer in the 4th quarter valued at $32,000. 68.36% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
PFE has been the subject of a number of analyst reports. Bank of America restated a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Truist Financial decreased their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. Finally, UBS Group cut their price target on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $31.92.
Get Our Latest Stock Analysis on PFE
Insider Activity at Pfizer
In related news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.06% of the stock is currently owned by insiders.
Pfizer Stock Performance
Shares of PFE stock traded down $0.58 during mid-day trading on Tuesday, reaching $25.56. The stock had a trading volume of 47,484,282 shares, compared to its average volume of 36,645,983. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The firm has a market cap of $144.96 billion, a price-to-earnings ratio of 18.13, a PEG ratio of 0.64 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The business's fifty day moving average is $26.15 and its 200-day moving average is $27.02.
Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the prior year, the company earned $0.10 EPS. Pfizer's quarterly revenue was up 24.7% on a year-over-year basis. On average, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Recommended Stories
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
